Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer—When Policy Delays Care
This Viewpoint discusses insurance barriers to next-generation sequencing (NGS) testing for patients with non–small cell lung cancer and proposes policy solutions to address these barriers.
Authors
- Nirmal Choradia (ORCID: https://orcid.org/0000-0002-7563-234X)
- Abdul Rafeh Naqash (ORCID: https://orcid.org/0000-0001-7622-720X)
- Aakash Desai
Institutions
- University of Oklahoma Medical Center (US)
- University of Alabama at Birmingham (US)
- Oklahoma State University Oklahoma City (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1001/jamaoncol.2025.6459
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00